<DOC>
	<DOCNO>NCT02756663</DOCNO>
	<brief_summary>The purpose study investigate anti-myeloma effect panobinostat give two different dos ( 10 mg 20 mg oral ) combination carfilzomib ( 20/56 mg/m2 i.v . ) low dose dexamethasone ( 20 mg oral ) v carfilzomib plus low-dose dexamethasone patient relapse relapsed refractory multiple myeloma . Safety efficacy evaluate . Treatment administer 4-week cycle patient discontinue due disease progression unacceptable toxicity reason . Patients discontinue study treatment reason document disease progression follow disease assessment every 8 week progression . All patient follow survival 3 year pass entry study , discontinue follow earlier .</brief_summary>
	<brief_title>Panobinostat Combination With Carfilzomib Dexamethasone Relapsed Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Previous diagnosis MM base IMWG definition ( Rajkumar , 2014 ) Prior treatment 1 3 prior line therapy Relapsed relapsed refractory MM Measureable disease screen base central laboratory assessment ECOG Performance status ≤ 2 Acceptable lab value prior start study treatment Primary refractory myeloma Prior treatment DAC inhibitor include panobinostat Prior treatment carfilzomib Allogeneic stem cell transplant recipient graft versus host disease ( either active require immunosuppression ) Any concomitant anticancer therapy besides study treatment ( bisphosphonates permit commenced prior start screen period ) Intolerance dexamethasone contraindication carfilzomib dexamethasone Unresolved diarrhea ≥ CTCAE grade 2 medical condition associate chronic diarrhea ( irritable bowel syndrome , inflammatory bowel disease ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>relapse</keyword>
	<keyword>relapse refractory</keyword>
	<keyword>panobinostat</keyword>
	<keyword>LBH589</keyword>
	<keyword>histone deacetylase inhibitor</keyword>
	<keyword>carfilzomib</keyword>
	<keyword>proteasome inhibitor</keyword>
</DOC>